Sovaldi Debate Hurts Access for Opioid Treatment Patients (Pharmalot Blog) The tussle over the cost of the Sovaldi hepatitis C medication may prevent yet another segment of the population from being treated — people who are enrolled in opioid treatment programs. Blogger Ed Silverman explains.
